Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07311564) titled 'A Study of LAD603 in Adults With Alopecia Areata' on Dec. 29, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Almirall, S.A.
Condition:
Alopecia Areata
Intervention:
Drug: LAD603
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: December 17, 2025
Target Sample Size: 136
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07311564
Published by HT Digital Content Services with permissio...